While all poly ADP-ribose polymerase (PARP) inhibitors improved progression-free survival, olaparib significantly extended overall survival (OS), making it a preferred option.

These are known as disease-modifying treatments and have been licensed for private use. Other medications are under review to see if they could be prescribed to people in the very early stages of ...